PedAM
Pediatric Disease Annotations & Medicines
| Disease | prostate cancer |
| Phenotype | C0011847|diabetes |
| Sentences | 33 |
| PubMedID- 23251408 | Of course, this should be investigated in future studies, since reduced igf-1 receptor availability in prostate cancer in patients with type 2 diabetes could make them more likely to respond to certain radio- or chemotherapies [23], [24], but might make them resistant to treatments that directly target the igf-1 receptor [24]. |
| PubMedID- 25451829 | Conclusions: prolonged androgen deprivation therapy exposure increases the risk of cardiovascular disease and diabetes in men diagnosed with prostate cancer who are older than approximately 75 years, especially those with other comorbidities. |
| PubMedID- 22792092 | The relevance of lower psa levels to the reduced risk of prostate cancer in men with diabetes is thus equivocal, but men with diabetes potentially have more advanced disease at diagnosis where their psa level reaches a certain cut-off/threshold. |
| PubMedID- 22474455 | We reported the first case about apatient who has central diabetes insipidus with metastatic prostate cancer due to only posterior pituitary metastasis. |
| PubMedID- 21667068 | There were no significant effect modifications by testosterone levels, bmi, race, diabetes, family history of prostate cancer, or cause of cancer diagnosis (data not shown).table 2prostate cancer risk by quartiles of serum estrone and estradiol concentrations in the placebo arm of the pcptall prostate cancergleason score < 7gleason score ≥ 7na (case/control)orb (95% ci)orc (95% ci)na (case/control)orb (95% ci)orc (95% ci)na (case/control)orb (95% ci)orc (95% ci)estrone (pg/ml)q1 (< 36.6)296/2921.001.00219/2921.001.0064/2921.001.00q2 (36.6–44.4)241/2670.89 (0.70–1.13)0.89 (0.70–1.13)197/2670.99 (0.76–1.28)0.98 (0.76–1.27)33/2670.57 (0.36–0.89)0.57 (0.36–0.89)q3 (44.5–54.1)249/2391.07 (0.84–1.37)1.06 (0.83–1.36)189/2391.11 (0.86–1.45)1.09 (0.84–1.42)52/2390.99 (0.66–1.48)1.00 (0.66–1.50)q4 (≥ 54.2)234/2141.19 (0.93–1.54)1.17 (0.90–1.51)166/2141.17 (0.88–1.54)1.13 (0.85–1.49)56/2141.21 (0.80–1.82)1.23 (0.81–1.86)trend p-value0.110.160.200.330.180.18estradiol (pg/ml)q1 (≤ 26.7)272/2801.001.00209/2801.001.0054/2801.001.00q2 (26.8–33.0)267/2621.08 (0.85–1.37)1.06 (0.83–1.36)208/2621.09 (0.84–1.41)1.07 (0.82–1.39)49/2620.98 (0.64–1.50)0.98 (0.64–1.51)q3 (33.1–39.4)237/2511.02 (0.79–1.31)1.00 (0.77–1.29)163/2510.92 (0.70–1.20)0.88 (0.67–1.17)58/2511.20 (0.80–1.82)1.21 (0.79–1.85)q4 (> 39.4)252/2301.23 (0.95–1.59)1.20 (0.91–1.56)195/2301.25 (0.95–1.65)1.19 (0.89–1.59)48/2301.11 (0.71–1.73)1.11 (0.70–1.76)trend p-value0.180.290.280.480.460.47for the majority of the men in the placebo arm, serum samples collected at baseline and at year 3 was pooled before estrogen analysis. |
| PubMedID- 22413038 | People tend to consume more animal foods and less plants, and the prevalence of obesity, cardiovascular diseases, diabetes mellitus, along with prostate cancer and breast cancer have increased during that time [10,11]. |
| PubMedID- 19998368 | Furthermore, the association of diabetes with prostate cancer was not altered when the snps were included in the logistic model. |
| PubMedID- 20056618 | The association of diabetes with prostate cancer outcomes is less clear. |
| PubMedID- 26559055 | Although most studies conducted in western countries suggest a lower risk of prostate cancer in patients with type 2 diabetes mellitus [13], studies conducted in taiwan and china do not conclude similarly and on the contrary support a higher risk of prostate cancer in patients with type 2 diabetes mellitus in terms of incidence [14,15], prevalence [16] and mortality [17]. |
| PubMedID- 20203524 | Genetic susceptibility to type 2 diabetes is associated with reduced prostate cancer risk. |
| PubMedID- 22299039 | diabetes is inversely associated with prostate cancer [19], but positively associated with endometrial cancer [20]. |
| PubMedID- 21070583 | Conclusion * prostate cancer survivors with comorbid diabetes have poorer general and cancer-specific hrql than those without diabetes. |
| PubMedID- 23193118 | Association of type 2 diabetes susceptibility variants with advanced prostate cancer risk in the breast and prostate cancer cohort consortium. |
| PubMedID- 23082075 | The significantly higher risk of prostate cancer associated with diabetes in the taiwanese population in this study is consistent with a previously published paper from taiwan [3], but is contrary to a significantly lower risk observed in caucasian people [4]. |
| PubMedID- 20473853 | Association of diabetes mellitus with prostate cancer: nested case-control study (prostate testing for cancer and treatment study). |
| PubMedID- 24475900 | No correlations were noted between overall b-cell density or intra-tumoral b cell density compared to age, body mass index, race, hypertension, hypercholesterolemia, diabetes, family history of prostate cancer, coronary artery disease or history of 5-alpha reductase inhibitors (all p > 0.05). |
| PubMedID- 23408570 | However, diabetes was inversely associated with prostate cancer (hr 0.74, 95% ci 0.70-0.78), which constituted 42% of cancers in men. |
| PubMedID- 20219288 | Are microvascular complications of diabetes mellitus really associated with prostate cancer. |
| PubMedID- 21750171 | Conclusions: we did not find evidence of association of this set of diabetes risk alleles with prostate cancer. |
| PubMedID- 19996060 | Background: previous studies indicate that androgen deprivation therapy for prostate cancer is associated with diabetes and cardiovascular disease among older men. |
| PubMedID- 21562753 | Objective: to analyze the association of diabetes mellitus (dm) with risk of prostate cancer and cancer grade among men undergoing prostate biopsy and to analyze how obesity and race modify these associations. |
| PubMedID- 23304521 | This is consistent with the epidemiological evidence to show that subjects with diabetes have lower rates of prostate cancer [18]. |
| PubMedID- 20697428 | The absence of any significant association between obesity and diabetes with prostate cancer in this population has been reported previously(21). |
| PubMedID- 25066306 | The biological basis of the association of diabetes mellitus with prostate cancer incidence and prognosis remains unclear. |
| PubMedID- 22656412 | Objective: to investigate the association of diabetes mellitus (dm) with prostate cancer (pca) risk and grade among japanese patients undergoing extended biopsy and to investigate how obesity modifies these relationships. |
| PubMedID- 23573093 | In contrast, some studies suggest that diabetes may be protective of prostate cancer risk [45–47], perhaps due to the typically decreased levels of androgens in these men; prostate tumours are fuelled by androgens for growth and survival, and testosterone levels are typically lower in men with diabetes [46–48]. |
| PubMedID- 24761863 | Purpose: the aim of this study to analyze the association between history of diabetes mellitus (dm) with risk of prostate cancer (pca) and cancer grade among men undergoing radical prostatectomy for pca. |
| PubMedID- 21273499 | In the current study, although prostate cancer risk increased with increasing diabetes duration in unadjusted models (data not shown), the adjusted models showed that the highest risk was observed at diabetes duration of 1–3 years and then declined gradually (table 3). |
| PubMedID- 20518947 | It is important to mention that the occurrence of prostate cancer in patients with type 2 diabetes is lower than that seen in the general population. |
| PubMedID- 23009291 | Exclusion criteria were: diabetes, family history of prostate cancer, transvesical partial open prostatectomy, other primary malignancies, or pharmacological treatment with drugs that may modify adipose tissue gene expression (for example, anti-dislipidemics or anti-diabetics). |
| PubMedID- 21415239 | Patients and methods: records of consecutive prostate cancer patients with coexisting diabetes mellitus type 2 who were treated at the study institution between 15 july 1999 and 31 december 2008 were reviewed. |
| PubMedID- 24843658 | Exceptionally, the risk of prostate cancer in diabetes is significantly decreased17. |
| PubMedID- 23641353 | On the contrary, the rr of prostate cancer in diabetes is known to be lower and this is most likely attributed to the decreased testosterone levels in diabetic patients [16]. |
Page: 1